Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis
Clinical Infectious Diseases2007Vol. 45(8), pp. 1001–1007
Citations Over TimeTop 10% of 2007 papers
Hanneke M. J. Nijland, Rovina Ruslami, A. J. Suroto, David M. Burger, Bachti Alisjahbana, Reinout van Crevel, Rob E. Aarnoutse
Abstract
Coadministration of moxifloxacin with intermittently administered rifampicin and isoniazid results in reduced moxifloxacin plasma concentrations, which is most likely the result of induced glucuronidation or sulphation by rifampicin. Further studies are warranted to evaluate the impact of the interaction on the outcome of TB treatment.
Related Papers
- → Quantification of pyrazinamide, isoniazid, acetyl‐isoniazid, and rifampicin by a high‐performance liquid chromatography method in human plasma from patients with tuberculosis(2020)19 cited
- FORMULATION AND EVALUATION OFENTERIC COATED PELLETS OF RIFAMPICIN AND ISONIAZID WITH IMPROVED RIFAMPICIN STABILITY(2014)
- Effects of Aminosalicylic Acid on Peak Blood Concentration of Rifampicin(2012)
- Bactericidal Activity of Moxifloxacin onExponential and Stationary Phase Cultures ofMycobacterium tuberculosis(2009)
- Interaksi Metabolisme INH & Rifampisin Menggunakan Hepatosit Tikus(2000)